Gentium Announces Presentation of Preclinical and Clinical Data on Defibrotide at the 33rd World Congress of International Society of Hematology
VILLA GUARDIA (COMO), Italy, Sept. 14 /PRNewswire/ -- Gentium
S.p.A. (NASDAQ:GENT) (the "Company") today announced
that two posters and one oral presentation on defibrotide will be
presented at the 33rd World Congress of International Society of
Hematology to be held at the ICC Jerusalem International Convention
Center in Jerusalem, Israel, October 10-13, 2010.
Poster Session 1, Tuesday, October 12, 2010:
"Defibrotide downregulates heparanase expression in tumor cells"
(Abstract #330). C. Echart et. al., Gentium SpA, Como, Italy.
"Defibrotide protects endothelial cells from the complications
of stem cell transplantation" (Abstract #335). C. Echart et al.,
Gentium SpA, Como, Italy.
Oral Presentation, Hall A, Wednesday, October 13, 2010:
"Defibrotide prevents acute Graft-versus-Host disease in
pediatric stem cell transplantation: results of the prospective
phase II/III VOD-DF trial" (Abstract #386, ). S. Corbacioglu et
al., University of Regensburg, Germany.
For more details on the congress, please visit the official
congress web site:
http://www2.kenes.com/hematology/pages/home.aspx. About Gentium
Gentium S.p.A., located in Como, Italy, is a biopharmaceutical
company focused on the development and manufacture of drugs to
treat and prevent a variety of diseases and conditions, including
vascular diseases related to cancer and cancer treatments.
Defibrotide, the Company's lead product candidate, is an
investigational drug that has been granted Orphan Drug status by
the U.S. FDA and Orphan Medicinal Product Designation by the
European Commission both to treat and to prevent VOD and Fast Track
Designation by the U.S. FDA to treat VOD.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements." In
some cases, you can identify these statements by forward-looking
words such as "may," "might," "will," "should," "expect," "plan,"
"anticipate," "believe," "estimate," "predict," "potential" or
"continue," the negative of these terms and other comparable
terminology. These statements are not historical facts but instead
represent the Company's belief regarding future results, many of
which, by their nature, are inherently uncertain and outside the
Company's control. It is possible that actual results, including
with respect to any financial forecast or the possibility of any
future regulatory approval, may differ materially from those
anticipated in these forward-looking statements. For a discussion
of some of the risks and important factors that could affect future
results, see the discussion in our Form 20-F filed with the
Securities and Exchange Commission under the caption "Risk
Gentium S.p.A. Salvatore Calabrese, +39 031-385-287 Senior Vice President, Finance firstname.lastname@example.org or The Trout Group Marcy Nanus, +1 646-378-2927 email@example.com
Source: Gentium S.p.A.
Posted: September 2010